NMRA Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: Neumora Therapeutics, Inc.

Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

a month ago - By: Neumora Therapeutics, Inc.

Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

a month ago - By: Neumora Therapeutics, Inc.

Neumora Therapeutics to Participate in Upcoming Conferences in November

a month ago - By: Neumora Therapeutics, Inc.

Neumora Therapeutics to Participate in Upcoming Conferences in November

4 months ago - By: Benzinga - Mentions: OEC VTLE DIN INSE ...

Earnings Scheduled For August 6, 2025

a month ago - By: Benzinga - Mentions: DYN PRE GNTA RNA ...

12 Health Care Stocks Moving In Monday's Pre-Market Session

a month ago - By: Neumora Therapeutics, Inc.

Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898

a month ago - By: Neumora Therapeutics, Inc.

Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898

a month ago - By: Stocktwits - Mentions: VHT SCHA

Neumora Therapeutics’ Experimental Drug Demonstrates Weight Loss in Preclinical Studies

a month ago - By: Neumora Therapeutics, Inc.

Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model

a month ago - By: Neumora Therapeutics, Inc.

Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model

2 months ago - By: Neumora Therapeutics, Inc.

Neumora Therapeutics to Host Virtual R&D Day on October 27

2 months ago - By: Neumora Therapeutics, Inc.

Neumora Therapeutics to Host Virtual R&D Day on October 27

3 months ago - By: Neumora Therapeutics, Inc.

Neumora Therapeutics to Participate in Upcoming Conferences in September

3 months ago - By: Neumora Therapeutics, Inc.

Neumora Therapeutics to Participate in Upcoming Conferences in September

4 months ago - By: The Motley Fool

Neumora (NMRA) Q2 Loss Improves 10%

4 months ago - By: Neumora Therapeutics, Inc.

Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

4 months ago - By: Neumora Therapeutics, Inc.

Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

4 months ago - By: Yahoo Finance

Mizuho Raises Price Target for Neumora (NMRA), Keeps Outperform Rating

5 months ago - By: Neumora Therapeutics, Inc.

Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

5 months ago - By: Neumora Therapeutics, Inc.

Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

5 months ago - By: Yahoo Finance

Mizuho Lifts PT on Neumora Therapeutics (NMRA) to $5 from $4, Keeps Outperform Rating

5 months ago - By: Neumora Therapeutics, Inc.

Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861

5 months ago - By: Neumora Therapeutics, Inc.

Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861

7 months ago - By: Kuehn Law, PLLC

Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law Firm

7 months ago - By: Neumora Therapeutics, Inc.

Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

7 months ago - By: Neumora Therapeutics, Inc.

Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

7 months ago - By: Neumora Therapeutics, Inc.

NEUMORA THERAPEUTICS INC (NMRA) Stock News

NMRA Latest News, Press Relases and Analysis

Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Neumora Therapeutics to Participate in Upcoming Conferences in November

Neumora Therapeutics to Participate in Upcoming Conferences in November

Earnings Scheduled For August 6, 2025

12 Health Care Stocks Moving In Monday's Pre-Market Session

Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898

Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898

Neumora Therapeutics’ Experimental Drug Demonstrates Weight Loss in Preclinical Studies

Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model

Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model

Neumora Therapeutics to Host Virtual R&D Day on October 27

Neumora Therapeutics to Host Virtual R&D Day on October 27

Neumora Therapeutics to Participate in Upcoming Conferences in September

Neumora Therapeutics to Participate in Upcoming Conferences in September

Neumora (NMRA) Q2 Loss Improves 10%

Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Mizuho Raises Price Target for Neumora (NMRA), Keeps Outperform Rating

Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

Mizuho Lifts PT on Neumora Therapeutics (NMRA) to $5 from $4, Keeps Outperform Rating

Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861

Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861

Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law Firm

Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025